Constitutional delay of growth and puberty: from presentation to final height.
This retrospective study evaluated clinical characteristics of patients with constitutional delay of growth and puberty (CDGP) at presentation, during puberty and at final height. The records of 151 children (105 boys, 46 girls) with CDGP were reviewed and the results were evaluated with respect to findings in healthy Turkish schoolchildren. CDGP was twice as frequent in boys as in girls. Height and weight deficit and short sitting height of the children were evident at presentation and continued up to final height. Mean age of onset of puberty was retarded by 2.5 years in girls and by 3 years in boys. The time between onset of puberty and pubertal growth spurt was shorter in both girls and boys than in the controls. Peak growth velocity was compromised in both girls and boys. Forty-one patients (30 boys, 11 girls) reached final height (FH). Mean FH was shorter than both target height and predicted adult height. The Bayley-Pinneau method was found to be a better predictor of FH than either the Tanner-Whitehouse method or target height. FH also showed correlation with the father's height. There was no effect of testosterone treatment on final height. Height deficit at onset of puberty, shorter duration between onset of puberty and pubertal growth spurt, compromised peak growth velocity and short upper segment due to delayed puberty, are findings which may explain the decreased final height of children with CDGP.
Poyrazoğlu
Sükran
S
Department of Growth & Development and Pediatric Endocrinology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Günöz
Hülya
H
Darendeliler
Feyza
F
Saka
Nurçin
N
Bundak
Rüveyde
R
Baş
Firdevs
F
D000293:Adolescent; D000365:Age Determination by Skeleton; D000704:Analysis of Variance; D000886:Anthropometry; D001827:Body Height / Q000502:physiology*; D001846:Bone Development / Q000502:physiology*; D002648:Child; D005260:Female; D006130:Growth Disorders / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D008297:Male; D011627:Puberty / Q000502:physiology*; D011628:Puberty, Delayed / Q000150:complications* / Q000188:drug therapy; D012189:Retrospective Studies; D012737:Sex Factors; D018709:Statistics, Nonparametric; D013739:Testosterone / Q000627:therapeutic use
D013739:Testosterone